Almirall, S.A. (LBTSF)
| Market Cap | 3.46B +68.2% |
| Revenue (ttm) | 1.27B +13.8% |
| Net Income | 49.33M |
| EPS | 0.23 |
| Shares Out | n/a |
| PE Ratio | 70.05 |
| Forward PE | 34.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 812 |
| Open | 15.35 |
| Previous Close | 15.35 |
| Day's Range | 15.35 - 15.35 |
| 52-Week Range | 9.01 - 15.47 |
| Beta | 0.17 |
| RSI | 65.04 |
| Earnings Date | Feb 23, 2026 |
About Almirall
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immun... [Read more]
Full Company ProfileNews
Almirall, S.A. (LBTSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Almirall Announces "LumiNE", a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a...
Almirall, S.A. (LBTSF) Q3 2025 Earnings Call Transcript
Almirall, S.A. (OTCPK:LBTSF) Q3 2025 Earnings Call November 10, 2025 4:00 AM EST Company Participants Pablo Divasson Fraile - Senior Director of Investor Relations Carlos Gallardo Piqué - CEO, Preside...
Almiralll, S.A. (LBTSF) Q2 2025 Earnings Call Transcript
Almiralll, S.A. (OTCPK:LBTSF) Q2 2025 Earnings Conference Call July 25, 2025 4:00 AM ET Company Participants Carlos Gallardo Piqué - CEO, President, Member of Management Board & Chairman of the Board ...
Almiralll, S.A. (LBTSF) Q1 2025 Earnings Call Transcript
Almiralll, S.A. (OTCPK:LBTSF) Q1 2025 Results Conference Call May 12, 2025 4:00 AM ET Company Participants Pablo Divasson - Investor Relations Carlos Gallardo - President & Chief Executive Officer Kar...
Almiralll, S.A. (LBTSF) Q4 2024 Earnings Call Transcript
Almiralll, S.A. (LBTSF) Q4 2024 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q3 2024 Earnings Call Transcript
Almirall, S.A. (OTCPK:LBTSF) Q3 2024 Earnings Conference Call November 11, 2024 4:00 AM ET Company Participants Pablo Divasson - Investor Relations Carlos Gallardo - President & Chief Executive Office...
Almirall, S.A. (LBTSF) Q2 2024 Earnings Call Transcript
Almirall, S.A. (OTCPK:LBTSF) Q2 2024 Earnings Conference Call July 22, 2024 4:00 AM ET Company Participants Pablo Divasson - Investor Relations Carlos Gallardo - President & Chief Executive Officer Ka...
Almirall, S.A. (LBTSF) Q1 2024 Earnings Call Transcript
Almirall, S.A. (OTCPK:LBTSF) Q1 2024 Results Conference Call May 13, 2024 4:00 AM ET Company Participants Pablo Divasson - Director, IR and Corporate Communications Carlos Gallardo - Chairman and CEO ...
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered str...
Almirall, S.A. (LBTSF) Q4 2023 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q4 2023 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q3 2023 Earnings Call Transcript
Almirall, S.A. (OTCPK:LBTSF) Q3 2023 Earnings Conference Call November 9, 2023 4:00 AM ET Company Participants Pablo Divasson - Director, Investor Relations and Corporate Communications Carlos Gallard...
Almirall, S.A. (LBTSF) Q2 2023 Earnings Call Transcript
Almirall, S.A. (OTCPK:LBTSF) Q2 2023 Earnings Conference Call July 24, 2023 4:00 AM ET Company Participants Pablo Divasson - Director of Investor Relations and Corporate Communications Carlos Gallardo...